Dexamethasone Sodium Phosphate
Dexamethasone Sodium Phosphate
9 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Dexamethasone Sodium Phosphate
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Gland Pharma Limited | unknown | 3 | SUPPLYING |
| Somerset Therapeutics, LLC | unknown | 3 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 3 | SUPPLYING |
| HF Acquisition Co LLC, DBA HealthFirst | unknown | 3 | SUPPLYING |
| Medical Purchasing Solutions, LLC | unknown | 2 | SUPPLYING |
| Asclemed USA, Inc. | unknown | 1 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 1 | SUPPLYING |
| Henry Schein, Inc. | unknown | 1 | SUPPLYING |
| Civica, Inc. | unknown | 1 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Dexamethasone Sodium Phosphate Injection — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology.
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). — Recalling firm: West-Ward Pharmaceuticals Corp. — Nationwide in the USA and Puerto Rico
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). — Recalling firm: West-Ward Pharmaceuticals Corp. — Nationwide in the USA and Puerto Rico